LBO France has sold Dutscher Group, a specialty laboratory supply distributor serving European research institutions and diagnostic labs, to Vivo Capital in a secondary buyout that closes the Paris-based sponsor's hold period on the platform. The transaction, announced this week without disclosed terms, moves a €300 million+ revenue business from one private equity owner to another at a moment when lab supply chains are consolidating and healthcare-focused capital is hunting scaled distribution assets.

Dutscher operates as a specialty catalog house and logistics provider for life sciences research consumables—pipette tips, reagents, diagnostic kits, cold-chain storage—selling into university labs, hospital pathology departments, and contract research organizations across France, Germany, and the Benelux region. LBO France acquired the business in 2019 through its LBO France XII fund, backing management's build-out of a pan-European fulfillment network and ERP integration that standardized inventory turns across 12 distribution centers. The platform grew organically and through three bolt-on acquisitions during the hold, including a German diagnostics consumables distributor in 2021 and a Belgian cold-chain logistics provider in 2023. Vivo Capital, a Palo Alto-based healthcare investor managing $8.2 billion, enters with a thesis around owning the last-mile supply relationship in European lab infrastructure as diagnostic volumes grow and academic procurement shifts to fewer, larger distributors.

The exit timing reflects two converging pressures in middle-market healthcare services. First, sponsor-to-sponsor secondary volume in European healthcare distribution has risen 40% year-over-year as strategic buyers pull back from non-core supply chain assets and PE funds holding post-pandemic healthcare bets face capital return deadlines. Second, Vivo's entry signals that U.S. healthcare capital is now willing to pay premium multiples for European distribution platforms that touch regulated end-users and offer subscription-like revenue visibility. Dutscher's customer base—university labs on multi-year procurement contracts, hospital systems with centralized buying—delivers 85%+ revenue retention and predictable working capital cycles that healthcare growth funds value more than commodity distribution peers. The business also benefits from a regulatory moat: European medical device regulations require distributors to maintain certifications and traceability systems that favor incumbents over new entrants. LBO France likely secured a mid-teens EBITDA multiple, 2-3x above traditional distribution comps, because the buyer is underwriting a platform roll-up thesis rather than a standalone asset.

Allocators and operators should watch for follow-on M&A within 12-18 months as Vivo deploys acquisition capital against Dutscher's platform. Likely targets include regional lab supply distributors in Italy, Spain, and the Nordics, where fragmentation persists and family-owned businesses lack succession plans. Also watch for refinancing or dividend recap activity within 24 months if Dutscher hits its integration milestones and Vivo seeks to return early capital to LPs. The broader signal is that healthcare distribution assets with defensible customer relationships are now drawing pre-emptive secondary bids from U.S. capital, compressing hold periods and lifting exit multiples for European sponsors.

Vivo Capital closed its $3.2 billion Fund V in 2023 and has deployed roughly 30% of that capital into eight platform investments, most in U.S. healthcare services and medical technology. Dutscher marks the fund's first European distribution play.